Evaluation of the Exoskeleton ATLAS 2030 as Robot-assisted Physical Therapy to Children With Neuromuscular Diseases

April 6, 2021 updated by: MarsiBionics

Evaluation of the Safety of ATLAS 2030 in the Application of Robot-assisted Physical Therapy to Children With Neuromuscular Diseases Phase I

This study aims to evaluate the safety, usability and acceptability of a motorized mobility assistance exoskeleton. The protocol explores the use of the motorized device during static and dynamic rehabilitation sessions focused on walking and functional activities, with the expectation of evaluating the safety and usability of the device in the population studied. The protocol has been focused on defining how the device can be used appropriately in this population in a safe and effective manner by rehabilitation specialists. The study also aims to assess the safety of clinical staff who implement the intervention.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
6

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Madrid
      • Arganda Del Rey, Madrid, Spain, 28500
        • MarsiCare

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

3 years to 14 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Maximum user weight of 35 kg
  • Thigh length (distance from the greater trochanter to the lateral condyle of the tibia) from 24 cm to 40 cm.
  • Leg length (distance from the lateral condyle of the tibia to the lateral malleolus) from 23 to 39 cm.
  • Pelvis width (between greater trochanters) from 24 to 35 cm.
  • Ability to achieve ankle dorsiflexion to 90˚
  • 20º or more hip flessum.
  • 20º or more knee flessum.
  • No allergies to any of the ATLAS materials: cotton, nylon, polyester, polyamide, polyethylene or propylene.
  • Informed consent signed by legal guardians.
  • Confirmed diagnosis of cerebral palsy or neuromuscular disease affecting walking ability at early development stages
  • Stable medical condition with no changes in disease-specific medication in the last 6 months, and additional medication in the last month.
  • Patient being followed according to the recommended standards for his or her illness
  • Ability to maintain, spontaneously or with a brace, the head and trunk while standing and walking.
  • No need for daytime ventilation (have an oxygen saturation and PCO2 with normal ambient oxygen
  • Score on the FAC scale between 1 and 4 points
  • Not being able to walk without assistance

Exclusion Criteria:

  • Patient's inability to follow simple instructions and/or communicate discomfort.
  • Invasive or non-invasive daytime ventilation.
  • Orthostatic hypotension.
  • 20º or more hip flessum.
  • 20º or more knee flessum
  • Scoliosis with a Cobb angle of more than 25º that cannot wear a corset during the test.
  • Severe skin injury to the lower extremities.
  • Scheduled surgery (spine, extremities) during the period of the study or surgery performed (spine, extremities) in the last 6 months.
  • History of fracture without trauma.
  • History of traumatic bone fracture in lower limbs or pelvic girdle in the last 3 months
  • Not receiving regular standing rehabilitation sessions.
  • Absence of control of the head or trunk in an upright position without the possibility of wearing a corset during the use of the exoskeleton
  • Refusal of the patient or legal guardian to include the child in the study.
  • Skin problems (diseases, allergies, sensitivity ...) that prevent the use of exoskeleton accessories on the skin of patients.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention Group
9 treatment sessions will be performed with the ATLAS2030 exoskeleton. The rehabilitation sessions last approximately 90 minutes. Two sessions are scheduled per week, for two weeks.
Device: Exoskeleton rehabilitation
The participants will perform physical therapy with the ATLSA2030 device, for 90 minutes per session.
Other Names:
  • ATLAS2030
  • ATLAS
  • robot-assisted therapy

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Safety as number of serious device adverse events
Time Frame: after each use of exoskeleton, for 5 weeks
Presence of a serious device adverse events where the participant or therapist is involved
after each use of exoskeleton, for 5 weeks

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Fall Prevalence [number of falls during the using of the device]
Time Frame: During the use of the device, for 5 weeks
Number of falling events ocurred from the participant or therapist
During the use of the device, for 5 weeks
Skin integrity [number of skin injuries related to the device]
Time Frame: before and after each use of exoskeleton, for 5 weeks
skin integrity measured as the number of skin injuries
before and after each use of exoskeleton, for 5 weeks
Spasticity [Modified Ashworth Scale]
Time Frame: Before and after the use of the device, during 5 weeks
Spasticity registered before and after the use of the device
Before and after the use of the device, during 5 weeks
Physical evaluation [number of physical injuries detected]
Time Frame: Before and after the use of the device, during 5 weeks
Physical Evaluation as presence of tissue damage
Before and after the use of the device, during 5 weeks
Muscle Strength [measured with Hand Held Dynamometer in N]
Time Frame: At the first day, 3rd week and 5th week
Muscle Strength measured at hip, knee and ankle muscles
At the first day, 3rd week and 5th week
ROM [measured with goniometer]
Time Frame: At the first day, 3rd week and 5th week
Range of Movement
At the first day, 3rd week and 5th week
Functional Mobility [Functional Ambulation Category scale]
Time Frame: At the first day, 3rd week and 5th week
Functional Mobility with and without the device
At the first day, 3rd week and 5th week
Distance covered walking [6MWT]
Time Frame: At the first day, 3rd week and 5th week
6MWT recorded using the device
At the first day, 3rd week and 5th week
Device malfunction [as number and type of device malfunction]
Time Frame: During the use of the device, for 5 weeks
Any device malfunction will be recorded
During the use of the device, for 5 weeks
Safety as presence of adverse events or adverse device events
Time Frame: after each use of exoskeleton, for 5 weeks
Presence of a device adverse events where the participant or therapist is involved.
after each use of exoskeleton, for 5 weeks
Exercises [measured as time per exercise in seconds]
Time Frame: after each use of exoskeleton, for 5 weeks
Measured as time per event for at each therapy session.
after each use of exoskeleton, for 5 weeks
Transfers [measured as time to carry out the transfers in seconds]
Time Frame: At each use of exoskeleton, for 5 weeks
Measured as time to carry out the transfers
At each use of exoskeleton, for 5 weeks
Acceptability [number of participants which discontinue the participation during the trial in relation with the included participants]
Time Frame: At the end of the study, at the 5th week
Measured as abandon ratio
At the end of the study, at the 5th week
Accessibility [number of potential participants in relation with the included participants]
Time Frame: At the end of the study, at the 5th week
Measured as relation between number of participants and number of potential participants which weren't recruited
At the end of the study, at the 5th week
Pain [Wong-Baker FACES Pain Rating Scale]
Time Frame: Before and after the use of the device, during 5 weeks
Pain registered before and after the use of the device, by the participant and therapist. The options are from 1 to 6. A higher score means a worse outcome.
Before and after the use of the device, during 5 weeks
Fatigue [Borg Rating Scale of Perceived Exertion]
Time Frame: Before and after the use of the device, during 5 weeks
Fatigue registered before and after the use of the device, by the participant and therapist. Measured from 0 to 10, being 0 as fully rested and 10 very tired. A higher score means a worse outcome.
Before and after the use of the device, during 5 weeks
Heart rate [sphygmomanometer]
Time Frame: Before and after the use of the device, during 5 weeks
Number of heart bets per minute
Before and after the use of the device, during 5 weeks
System Usability [System Usability Scale]
Time Frame: At the end of the study, 5th week
Measurement of System's Usability measured by the therapist
At the end of the study, 5th week
User perception of the device [QUEST 2.0 and QUEST 2.1]
Time Frame: At the end of the study, 5th week
QUEST 2.0 will be assessed by the therapist, and QUEST 2.1 will be assessed by the participant
At the end of the study, 5th week
Particpant's stability [Functional Reach Test]
Time Frame: At the first day, 3rd week and 5th week
Functional Reach Test
At the first day, 3rd week and 5th week
Systolic/Diastolic Pressure [sphygmomanometer]
Time Frame: Before and after the use of the device, during 5 weeks
Systolic Pressure and Diastolic Pressure measured with sphygmomanometer (measured in mmHg)
Before and after the use of the device, during 5 weeks
Breath Rate [number of breaths per minute]
Time Frame: Before and after the use of the device, during 5 weeks
Number of breaths per minute
Before and after the use of the device, during 5 weeks
SpO2 [pulse oximeter]
Time Frame: Before and after the use of the device, during 5 weeks
SpO2 measured as %
Before and after the use of the device, during 5 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
MarsiBionics

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Hospital Universitario La Paz

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 15, 2020

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 31, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 3, 2020

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2021

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 8, 2021

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 8, 2021

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 6, 2021

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
April 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • ATLAS2030ENM-I

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings